# Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

> **NCT00470470** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 30 (actual)

## Conditions studied

- Acral Lentiginous Malignant Melanoma
- Recurrent Melanoma
- Stage IIIA Melanoma
- Stage IIIB Melanoma
- Stage IIIC Melanoma
- Stage IV Melanoma

## Interventions

- **DRUG:** imatinib mesylate
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00470470
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04
- **Primary completion:** 2013-12
- **Final completion:** 2014-10
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2014-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00470470

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00470470, "Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00470470. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*